Molecular Mechanism of Gleditsiae Spina for the Treatment of High-Grade Serous Ovarian Cancer Based on Network Pharmacology and Pharmacological Experiments

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"></td><td class="align_center">Luteolin</td><td class="align_center">Genistein</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">PIK3CA</td><td class="align_center">-8.49</td><td class="align_center">-8.59</td></tr><tr><td class="align_left">CTNNB1</td><td class="align_center">-8.47</td><td class="align_center">-7.56</td></tr><tr><td class="align_left">HSPE</td><td class="align_center">-8.97</td><td class="align_center">-7.35</td></tr><tr><td class="align_left">AKT1</td><td class="align_center">-8.22</td><td class="align_center">-8.79</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>The docking affinity value of compounds with core targets.</div>

BioMed Research International

tab3

Table 3

Table 3: Molecular Mechanism of Gleditsiae Spina for the Treatment of High-Grade Serous Ovarian Cancer Based on Network Pharmacology and Pharmacological Experiments 

Table 3 | Molecular Mechanism of Gleditsiae Spina for the Treatment of High-Grade Serous Ovarian Cancer Based on Network Pharmacology and Pharmacological Experiments 